GILD News and Press, Gilead Sciences Inc. From 05/30/24

2024-05-30 17:06:32 ET More on Gilead Sciences Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows Gilead partner...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy ® (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatme...

2024-05-29 10:47:04 ET CVS Health Corp (CVS) CVS is trading DOWN for the last 4 days, and it at trading at $55.80 with volume of 15,015,387 and a one day change of $-0.18 (-0.31%). CVS Health Corp has a 52-week low of 53.70 and a 52-week high of $83.25. The business's 50-day moving ...

2024-05-28 14:34:16 ET More on G1 Therapeutics G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeu...

2024-05-28 13:31:54 ET Summary On April 26, Gilead Sciences published financial results for the first quarter of 2024, which were better than I expected. So, total sales of oncology drugs amounted to $789 million, up about 18% yearly thanks to strong sales of Trodelvy. On May ...

2024-05-28 10:23:08 ET More on Gilead Sciences Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors ...

NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Gilead Sciences: In an effort to advance access to cancer prevention and early detection among U.S. workers, the Biden Cancer Moonshot recently announced a series of actions that organizations are taking to improve access and use of cancer screeni...

2024-05-28 09:45:00 ET Equities never follow a flawless, unimpeded upward path. Sometimes, even the strongest companies will encounter issues that will sink their stock prices. That's OK. The key to earning great returns over five years or more is sticking with those longtime winners, even ...

2024-05-27 13:07:50 ET Summary At this point, Gilead Sciences could only be fairly valued with trading for 10 times free cash flow. With Veklury sales close to a bottom, Gilead Sciences might finally start growing its top line again - acquisition might also contribute to growth. ...

2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...